Rockefeller Capital Management L.P. Akebia Therapeutics, Inc. Transaction History

Rockefeller Capital Management L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$0.72 - $2.93 $1,368 - $5,567	1,900 Added 101.55%	3,771 $2,000
Q2 2021 Aug 10, 2021	BUY	$2.83 - $4.2 $5,294 - $7,858	1,871 New	1,871 $7,000
Q4 2020 Feb 12, 2021	SELL	$2.22 - $3.78 $916 - $1,561	-413 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$2.39 - $13.08 $375 - $2,053	157 Added 61.33%	413 $1,000
Q2 2020 Aug 12, 2020	SELL	$6.67 - $13.58 $1,113 - $2,267	-167 Reduced 39.48%	256 $3,000
Q1 2020 May 12, 2020	BUY	$4.1 - $10.24 $1,734 - $4,331	423 New	423 $3,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.